Pancreatic Cancer Research

ResearcherUniversity of PittsburghActive in the last 2 years

Lee Mayer Ocuin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3341-9521; OpenAlex author ID A5037451734. Sources: ClinicalTrials.gov.

Their work

Papers
26 (first author 2, last author 14)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
33
Papers, trials and grants by year

2017: 3 papers · 2018: none · 2019: none · 2020: 3 papers · 2021: 7 papers · 2022: 6 papers · 2023: 3 papers · 2024: 3 papers, 1 trial · 2025: none · 2026: 1 paper

Papers 26

  1. Invited commentary on: "Post-surgical ctDNA as a prognostic biomarker for relapse of resected pancreatic ductal adenocarcinoma". First author DOI 10.1016/j.gassur.2026.102449↗
  2. Understanding surgical attrition for "resectable" pancreatic cancer. Co-author DOI 10.1016/j.hpb.2023.11.008↗
  3. To Revise or Not Revise? Isolated Margin Positivity in Localized Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1245/s10434-024-15616-y↗
  4. ASO Author Reflections: Isolated Margin Positivity in Localized Pancreatic Ductal Adenocarcinoma and Operative Margin Revision. First author DOI 10.1245/s10434-024-15658-2↗
  5. Disparities in guideline-compliant care for patients with pancreatic ductal adenocarcinoma at minority-versus non-minority-serving hospitals. Last author DOI 10.1016/j.hpb.2023.07.903↗
  6. An analysis of time to treatment in patients with pancreatic adenocarcinoma. Co-author DOI 10.1016/j.surg.2023.03.011↗
  7. Trends in and Prognostic Significance of Time to Treatment in Pancreatic Cancer: A Population-Based Study. Co-author DOI 10.1245/s10434-023-14221-9↗
  8. Weight loss during neoadjuvant therapy for pancreatic cancer does not predict poor outcomes. Last author DOI 10.1016/j.amjsurg.2021.10.001↗
  9. Combined multiagent chemotherapy and radiotherapy is associated with prolonged overall survival in patients with non-operatively managed stage II-III pancreati… Last author DOI 10.1016/j.hpb.2021.08.938↗
  10. Multimodal therapy with or without irreversible electroporation for unresectable locally advanced pancreatic adenocarcinoma: a systematic review and meta-analy… Last author DOI 10.1016/j.hpb.2021.12.014↗
  11. Average treatment effect of facility hepatopancreatobiliary cancer volume on survival of non-resected pancreatic adenocarcinoma. Last author DOI 10.1016/j.hpb.2022.07.007↗
  12. Time to Neoadjuvant Chemotherapy Initiation Is not Associated With Survival in Pancreatic Cancer. Last author DOI 10.1016/j.jss.2022.03.013↗
  13. A nationwide analysis of pancreatic cancer trial enrollment reveals disparities and participation problems. Last author DOI 10.1016/j.surg.2021.10.023↗
  14. The importance of time-to-adjuvant treatment on survival with pancreatic cancer: A systematic review and meta-analysis. Co-author DOI 10.1002/cnr2.1390↗
  15. The treatment sequence may matter in patients undergoing pancreatoduodenectomy for early stage pancreatic cancer in the era of modern chemotherapy. Last author DOI 10.1016/j.amjsurg.2020.10.030↗
  16. Facility volume-survival relationship in patients with early-stage pancreatic adenocarcinoma treated with neoadjuvant chemotherapy followed by pancreatoduodene… Last author DOI 10.1016/j.surg.2020.12.003↗
  17. Immunotherapy Is Associated with a Survival Benefit in Patients Receiving Chemotherapy for Metastatic Pancreatic Cancer. Last author DOI 10.1089/pancan.2021.0003↗
  18. Oncologic Outcomes of Robotic Left Pancreatectomy for Pancreatic Adenocarcinoma: A Single-Center Comparison to Laparoscopic Resection. Co-author DOI 10.1177/0003134820949524↗
  19. Pure and Hybrid Deep Learning Models can Predict Pathologic Tumor Response to Neoadjuvant Therapy in Pancreatic Adenocarcinoma: A Pilot Study. Last author DOI 10.1177/0003134820982557↗
  20. Neoadjuvant Radiotherapy is Associated With Improved Pathologic Outcomes and Survival in Resected Stage II-III Pancreatic Adenocarcinoma Treated With Multiagen… Last author DOI 10.1177/00031348211038581↗
  21. Neoadjuvant chemotherapy is associated with improved survival in patients with left-sided pancreatic adenocarcinoma. Co-author DOI 10.1002/jso.26196↗
  22. Factors Associated with Treatment and Survival of Early Stage Pancreatic Cancer in the Era of Modern Chemotherapy: An Analysis of the National Cancer Database. Last author DOI 10.1089/pancan.2020.0011↗
  23. A comprehensive analysis of clinical trials in pancreatic cancer: what is coming down the pike? Co-author DOI 10.18632/oncotarget.27727↗
  24. Analysis of Predictors of Resection and Survival in Locally Advanced Stage III Pancreatic Cancer: Does the Nature of Chemotherapy Regimen Influence Outcomes? Co-author DOI 10.1245/s10434-016-5707-0↗
  25. Failure to Treat: Audit of an Institutional Cancer Registry Database at a Large Comprehensive Cancer Center Reveals Factors Affecting the Treatment of Pancreat… Co-author DOI 10.1245/s10434-017-5880-9↗
  26. A margin distance analysis of the impact of adjuvant chemoradiation on survival after pancreatoduodenectomy for pancreatic adenocarcinoma. Co-author DOI 10.21037/jgo.2017.04.02↗

Trials 1

  1. CAPEcitabine eXtension of Adjuvant Therapy for Pancreatic Adenocarcinoma: (CAPE-X) Principal investigator NCT06110598↗

Closest collaborators

The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. John Brian Ammori · 17 shared papers, 2020–2024 · strength 2.62
  2. Jeffrey M. Hardacre · 17 shared papers, 2020–2024 · strength 2.62
  3. Jordan Michael Winter · 16 shared papers, 2020–2024 · strength 2.41
  4. Jonathan J. Hue · 14 shared papers, 2020–2024 · strength 2.11
  5. Luke Daniel Rothermel · 13 shared papers, 2020–2023 · strength 1.90
  6. Mohamedraed Elshami · 8 shared papers, 2022–2024 · strength 1.67
  7. Kavin Sugumar · 10 shared papers, 2021–2023 · strength 1.51
  8. David Lawrence Bajor · 7 shared papers, 2020–2023 · strength 0.95
  9. Alexander N German · 1 shared paper, 2026 · strength 0.63
  10. Sarah Coseo Markt · 4 shared papers, 2021–2022 · strength 0.56
  11. Richard S. Hoehn · 3 shared papers, 2022–2024 · strength 0.53
  12. John B. Martinie · 4 shared papers, 2020–2021 · strength 0.50
  13. David A. Iannitti · 4 shared papers, 2020–2021 · strength 0.50
  14. Michael David Watson · 4 shared papers, 2020–2021 · strength 0.50
  15. Erin H. Baker · 4 shared papers, 2020–2021 · strength 0.50
  16. Dionisios V. Vrochides · 4 shared papers, 2020–2021 · strength 0.50
  17. Shreya Gupta · 2 shared papers, 2023 · strength 0.36
  18. Hanna H. Kakish · 2 shared papers, 2022–2024 · strength 0.35
  19. Maria R. Baimas‐George · 2 shared papers, 2021 · strength 0.26
  20. Jennifer Anne Dorth · 2 shared papers, 2021–2022 · strength 0.26
  21. Erryk Katayama · 2 shared papers, 2020–2022 · strength 0.26
  22. Jennifer Lee Miller-Ocuin · 3 shared papers, 2017–2020 · strength 0.25
  23. Melissa Ellen Hogg · 3 shared papers, 2017 · strength 0.21
  24. Amer H. Zureikat · 3 shared papers, 2017 · strength 0.21
  25. Herbert J. Zeh · 3 shared papers, 2017 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.